Stock Events

Arcus Biosciences 

$19.53
14
-$0.14-0.71% Friday 21:00

Statistics

Day High
19.68
Day Low
18.8
52W High
25.47
52W Low
12.95
Volume
1,284,299
Avg. Volume
1,064,177
Mkt Cap
1.77B
P/E Ratio
-4.88
Dividend Yield
-
Dividend
-

Earnings

21FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-1.16
-1.07
-0.99
-0.9
Expected EPS
-1.02
Actual EPS
-1.08

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RCUS. It's not an investment recommendation.

Analyst Ratings

36$Average Price Target
The highest estimate is $50.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.
Show more...
CEO
Employees
236
Country
US
ISIN
US03969F1093

Listings